Novartis AG
A global medicines company that researches, develops, and markets healthcare products.
NOVN | SW
Overview
Corporate Details
- ISIN(s):
- CH0012005267 (+10 more)
- LEI:
- 5493007HIVTX6SY6XD66
- Country:
- Switzerland
- Address:
- LICHTSTR. 35, 4056 BASEL
- Website:
- https://www.novartis.com/
- Sector:
- Manufacturing
Description
Novartis AG is a global medicines company focused on the research, development, manufacturing, and marketing of innovative healthcare products. The company's mission is to reimagine medicine to improve and extend people's lives. By leveraging advanced science and technology, Novartis develops a portfolio of treatments across various therapeutic areas to address the evolving needs of patients and societies. The firm is committed to delivering high-value medicines that tackle some of the most challenging healthcare issues worldwide.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2017-12-15 07:00 |
Novartis announces Oncology head to retire
|
English | 15.2 KB | ||
| 2017-11-13 18:00 |
Novartis canakinumab (ACZ885) reduced cardiovascular risk by 25% in subgroup of…
|
English | 29.7 KB | ||
| 2017-11-13 07:00 |
Novartis highlights its differentiated late stage pipeline at the R&D update an…
|
English | 24.2 KB | ||
| 2017-11-13 03:51 |
Novartis brolucizumab (RTH258) demonstrates superiority versus aflibercept in k…
|
English | 31.6 KB | ||
| 2017-10-24 08:00 |
Novartis delivered growth on top and bottom line in all divisions in Q3
|
English | 128.5 KB | ||
| 2017-09-04 08:00 |
Novartis announces CEO Joseph Jimenez to retire from Novartis in 2018. Vasant N…
|
English | 19.8 KB | ||
| 2017-08-30 18:04 |
Novartis receives first ever FDA approval for a CAR-T cell therapy, Kymriah(TM)…
|
English | 37.2 KB | ||
| 2017-08-28 10:00 |
Novartis announces analysis published in The Lancet showing ACZ885 reduced lung…
|
English | 29.9 KB | ||
| 2017-08-28 10:00 |
Novartis Phase III CANTOS study demonstrates that targeting inflammation with A…
|
English | 28.2 KB | ||
| 2017-08-28 10:00 |
Novartis Phase III CANTOS study demonstrates that targeting inflammation with A…
|
English | 28.2 KB | ||
| 2017-07-18 08:00 |
Q2 results confirm full year guidance. Strong pipeline results underpin potenti…
|
English | 121.2 KB | ||
| 2017-07-13 00:24 |
Novartis CAR-T cell therapy CTL019 unanimously (10-0) recommended for approval …
|
English | 24.3 KB | ||
| 2017-06-22 08:15 |
Novartis Phase III study shows ACZ885 (canakinumab) reduces cardiovascular risk…
|
English | 24.4 KB | ||
| 2017-06-20 08:15 |
Novartis RTH258 (brolucizumab) demonstrates robust visual gains in nAMD patient…
|
English | 26.4 KB | ||
| 2017-05-31 08:00 |
At the Meet Novartis Management investor event, Novartis highlights focus on in…
|
English | 29.0 KB |
Automate Your Workflow. Get a real-time feed of all Novartis AG filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Novartis AG
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Novartis AG via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-04-30 | N/A | Executive member | Sell | None | 1,973,993.83 CHF |
| 2025-03-07 | N/A | Non-Executive member | Buy | None | 160,000.00 CHF |
| 2025-02-11 | N/A | Executive member | Sell | None | 312,203.18 CHF |
| 2025-02-07 | N/A | Executive member | Sell | None | 2,500,278.74 CHF |
| 2025-02-05 | N/A | Executive member | Sell | None | 1,365,687.19 CHF |
| 2025-02-04 | N/A | Executive member | Sell | None | 1,840,201.00 CHF |
| 2025-01-30 | N/A | Executive member | Buy | None | 699,424.74 CHF |
| 2025-01-30 | N/A | Executive member | Buy | None | 698,883.18 CHF |
| 2024-12-19 | N/A | Executive member | Sell | None | 1.00 CHF |
| 2024-11-29 | N/A | Executive member | Sell | None | 167,294.98 CHF |
Peer Companies
